Xiaoyan Xu

Ms. Xiaoyan Xu

University College London School of Pharmacy
orcid

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2021 in Journal of Controlled Release
Verified
Journal Article
Closed access
Xiaoyan XuXiaoyan Xu
Xiaoyan Xu
Atheer AwadAtheer Awad
Atheer Awad
PRPamela Robles-Martinez
Pamela Robles-Martinez
Simon GaisfordSimon Gaisford
Simon Gaisford
AGAlvaro Goyanes
Alvaro Goyanes
ABAbdul W Basit
Abdul W Basit

11 June 2019 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PMPamela Robles Martinez
Pamela Robles Martinez
Xiaoyan XuXiaoyan Xu
Xiaoyan Xu
STSarah Trenfield
Sarah Trenfield
Atheer AwadAtheer Awad
Atheer Awad
AGAlvaro Goyanes
Alvaro Goyanes
Simon GaisfordSimon Gaisford
Simon Gaisford
Three-dimensional printing (3DP) has demonstrated great potential for multi-material fabrication because of its capability for printing bespoke and spatially separated material conformations. Such a concept could revolutionise the pharmaceutical industry, enabling the production of personalised, multi-layered drug products on demand. Here, we developed a novel stereolithographic (SLA) 3D printing method that, for the first time, can be used to fabricate multi-layer constructs (polypills) with variable drug content and/or shape. Using this technique, six drugs, including paracetamol, caffeine, naproxen, chloramphenicol, prednisolone and aspirin, were printed with different geometries and material compositions. Drug distribution was visualised using Raman microscopy, which showed that whilst separate layers were successfully printed, several of the drugs diffused across the layers depending on their amorphous or crystalline phase. The printed constructs demonstrated excellent physical properties and the different material inclusions enabled distinct drug release profiles of the six actives within dissolution tests. For the first time, this paper demonstrates the feasibility of SLA printing as an innovative platform for multi-drug therapy production, facilitating a new era of personalised polypills.

1 January 2021 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
Xiaoyan XuXiaoyan Xu
Xiaoyan Xu
AGAlvaro Goyanes
Alvaro Goyanes
STSarah J. Trenfield
Sarah J. Trenfield
LDLuis Diaz-Gomez
Luis Diaz-Gomez
CACarmen Alvarez-Lorenzo
Carmen Alvarez-Lorenzo
ABAbdul W Basit
Abdul W Basit

1 May 2020 in Additive Manufacturing
Verified
Journal Article
Closed access
Xiaoyan XuXiaoyan Xu
Xiaoyan Xu
PRPamela Robles-Martinez
Pamela Robles-Martinez
CMChristine M. Madla
Christine M. Madla
FJFanny Joubert
Fanny Joubert
AGAlvaro Goyanes
Alvaro Goyanes
SGSimon Gaisford
Simon Gaisford

17 November 2020 in Pharmaceutics
Verified
Journal Article
Open access
PDF file
PJPatricija Januskaite
Patricija Januskaite
Xiaoyan XuXiaoyan Xu
Xiaoyan Xu
SRSejal R Ranmal
Sejal R Ranmal
Simon GaisfordSimon Gaisford
Simon Gaisford
ABAbdul W Basit
Abdul W Basit
AGAlvaro Goyanes
Alvaro Goyanes
3D printing (3DP) in the pharmaceutical field is a disruptive technology that allows the preparation of personalised medicines at the point of dispensing. The paediatric population presents a variety of pharmaceutical formulation challenges such as dose flexibility, patient compliance, taste masking and the fear or difficulty to swallow tablets, all factors that could be overcome using the adaptable nature of 3DP. User acceptability studies of 3D printed formulations have been previously carried out in adults; however, feedback from children themselves is essential in establishing the quality target product profile towards the development of age-appropriate medicines. The aim of this study was to investigate the preference of children for different 3D printed tablets (Printlets™) as an important precursor to patient acceptability studies. Four different 3DP technologies; digital light processing (DLP), selective laser sintering (SLS), semi-solid extrusion (SSE) and fused deposition modeling (FDM) were used to prepare placebo printlets with similar physical attributes including size and shape. A single-site, two-part survey was completed with participants aged 4–11 years to determine their preference and opinions based on visual inspection of the printlets. A total of 368 participants completed an individual open questionnaire to visually select the best and worst printlet, and 310 participants completed further non-compulsory open questions to elaborate on their choices. Overall, the DLP printlets were the most visually appealing to the children (61.7%) followed by the SLS printlets (21.2%), and with both the FDM (5.4%) and SSE (11.7%) printlets receiving the lowest scores. However, after being informed that the SSE printlets were chewable, the majority of participants changed their selection and favoured this printlet, despite their original choice, in line with children’s preference towards chewable dosage forms. Participant age and sex displayed no significant differences in printlet selection. Printlet descriptions were grouped into four distinct categories; appearance, perceived taste, texture and familiarity, and were found to be equally important when creating a quality target product profile for paediatric 3D printed formulations. This study is the first to investigate children’s perceptions of printlets, and the findings aim to provide guidance for further development of paediatric-appropriate medicines using different 3DP technologies.

1 February 2021 in Materials Science and Engineering: C
Verified
Journal Article
Closed access
MVMaría Vivero-Lopez
María Vivero-Lopez
Xiaoyan XuXiaoyan Xu
Xiaoyan Xu
AMAndrea Muras
Andrea Muras
AOAna Otero
Ana Otero
ACAngel Concheiro
Angel Concheiro
AGAlvaro Goyanes
Alvaro Goyanes